Sensorion appoints Aniz Girach as Independent Board Member
Retrieved on:
Tuesday, January 4, 2022
Biotechnology, Medical Devices, Health, Pharmaceutical, Clinical Trials, Hearing loss, Diagnosis, Retina, Book, Biomarker, ProQR, Board, Nightstar, Eli Lilly, Board of directors, Company, Usher syndrome, Mutation, Wills Eye Hospital, IOVS, Alcon, Deafness, Laboratory, Coronavirus Scientific Advisory Board (Turkey), MD, Thrombogenicity, Research, Therapy, Drug, Merck, Eye, GJB2, Industry, Pharmaceutical industry, Dentistry
Sensorion (Paris:ALSEN) (FR0012596468 ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, announces that Aniz Girach, MD, is joining the Board of directors as an independent Board member.
Key Points:
- Sensorion (Paris:ALSEN) (FR0012596468 ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, announces that Aniz Girach, MD, is joining the Board of directors as an independent Board member.
- His appointment will expand the number of independent Board members to four of a total of nine.
- Were thrilled that Aniz has joined the Board of Sensorion.
- Dr. Girach is an Honorary Professor at Wills Eye Hospital, Philadelphia, USA and a member of three Scientific Advisory Boards for international ophthalmic organizations.